Business
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone paymentAllows evaluation of potential for precision prevention of neurodegenerative diseasesData from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected Q2 2026 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical c
About this update from Ac Immune Sa
[{"type":"image","alt":"AC Immune SA","displaySize":"","headline":null,"caption":"AC Immune SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":240,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/3c2df2034a46edd1abf458c36df78606"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rg4iU.WIRmIIQ9OzQN6.PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMQ--/https://media.zenfs.com/en/globenewswire.com/3c2df2034a46edd1abf458c36df78606","width":240,"height":75}},"lazy":false},{"type":"text","content":"AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease","length":134,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone payment","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Allows evaluation of potential for precision prevention of neurodegenerative diseases","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Data from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected Q2 2026","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":262,"olType":false},{"type":"text","content":"Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial. As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners’ exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24 for the treatment of Alzheimer’s disease (AD).","length":575,"tagName":"p"},{"type":"text","content":"ABATE is assessing ACI-24 in subjects with prodromal AD and in adults with Down syndrome (DS). AD4 includes subjects with prodromal AD.","length":135,"tagName":"p"},{"type":"text","content":"Dr. Andrea Pfeifer, CEO of AC Immune SA, said: “This milestone underscores the progress in our Phase 1b/2 ABATE trial of ACI-24. AD4 will build on the encouraging early safety and immunogenicity data to date. It allows further evaluation of the potential of ACI-24 and, more broadly, our precision preventi...